Filtered By:
Source: Current Pharmaceutical Design

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Markers of early vascular ageing.
CONCLUSIONS: Vascular measurements may better represent the continuum of cardiovascular disease from a young healthy to an aged diseased vessel that is going to produce adverse clinical events. PMID: 28356037 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 28, 2017 Category: Drugs & Pharmacology Authors: Kotsis V, Antza C, Doundoulakis I, Stabouli S Tags: Curr Pharm Des Source Type: research

Climate Changes and Human Health: a review of the Effect of Environmental Stressors on Cardiovascular Diseases across Epidemiology and Biological Mechanisms.
CONCLUSION: Finally, we examine climate change implications on publich health and suggest adaptation strategies to monitor the high-risk population, and reduce the amount of hospital admissions associated to these events. Such interventions may minimize the costs of public health and reduce the mortality for cardiovascular diseases. PMID: 28317479 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 17, 2017 Category: Drugs & Pharmacology Authors: Giorgini P, Di Giosia P, Petrarca M, Lattanzio F, Stamerra CA, Ferri C Tags: Curr Pharm Des Source Type: research

Homocysteine and non-cardiac vascular disease.
Abstract Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are ...
Source: Current Pharmaceutical Design - March 17, 2017 Category: Drugs & Pharmacology Authors: Katsiki N, Perez-Martinez P, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

MicroRNAs as Big Regulators of Neural Stem/Progenitor Cell Proliferation, Differentiation and Migration: A Potential Treatment for Stroke.
CONCLUSION: Promising but full of hurdles, miRNAs have been confirmed to play a critical role in regulating NSPCs. Clinical potentials of miRNAs are huge in treating stroke patients receiving NSPCs-based therapy, which can be used as biomarkers for the diagnosis and prognosis, and as targets for controlling the proliferation, differentiation and migration of NSPCs. PMID: 28245761 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 27, 2017 Category: Drugs & Pharmacology Authors: Zhang Q, Zhang K, Zhang C, Ge H, Yin Y, Feng H, Hu R Tags: Curr Pharm Des Source Type: research

Lenticulostriate artery and Lenticulostriate-artery Neural Complex: New concept for Intracerebral Hemorrhage.
CONCLUSION: LSAs and the circumferential deep brain are an interactive and mutually affected entity. We propose a new concept called lenticulostriate-artery neural complex (LNC) to integrate the structural, functional and pathological characteristics of this area, which would be a pragmatic paradigm in directing the future basic and clinical studies on ICH. PMID: 28228074 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2017 Category: Drugs & Pharmacology Authors: Hu R, Feng H Tags: Curr Pharm Des Source Type: research

Nutraceuticals and dietary supplements to improve quality of life and outcomes in heart failure patients.
CONCLUSIONS: Evidence suggests that the supplementation with nutraceuticals may be a useful option for effective management of HF, with the advantage of excellent clinical tolerance. PMID: 28120718 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 23, 2017 Category: Drugs & Pharmacology Authors: Cicero AF, Colletti A Tags: Curr Pharm Des Source Type: research

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management.
CONCLUSION: Multiple metabolic benefits may account for the positive clinical outcomes in the EMPA-REG OUTCOME study. Ongoing CV outcome trials involving other SGLT2i will help establish whether the reported CV and microvascular risk benefits are compound-specific or drug class effects. PMID: 28088910 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 12, 2017 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Theodorakis MJ Tags: Curr Pharm Des Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

Endothelial Progenitor Cells As A Therapeutic Approach For Intracerebral Hemorrhage.
CONCLUSION: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH. PMID: 28003010 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Pías-Peleteiro J, Campos F, Pérez-Mato M, López-Arias E, Rodríguez-Yáñez M, Castillo J, Sobrino T Tags: Curr Pharm Des Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

Antithrombotic treatment management in patients with intracerebral hemorrhage: reversal and restart.
CONCLUSION: Although no one can deny the usefulness of antithrombotic therapy a therapeutic strategy should be developed in order to optimize the clinical decision of stopping, reversing and restarting antithrombotic treatment. This review concludes in strong recommendations, yet a multidisciplinary panel by a stroke physician or neurologist, a cardiologist, a neuroradiologist and a neurosurgeon should evaluate the benefits and the risks for each patient and decide the best therapeutic strategy. PMID: 27917716 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 4, 2016 Category: Drugs & Pharmacology Authors: Giakoumettis D, Alexiou GA, Vrachatis DA, Themistoklis K, Stathis P, Vavuranakis M, Themistocleous MS Tags: Curr Pharm Des Source Type: research

Peri-procedural anticoagulation in catheter ablation for atrial fibrillation: a review.
Abstract Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk from thromboembolic events. Long-term stroke risk and mortality has been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clin...
Source: Current Pharmaceutical Design - December 4, 2016 Category: Drugs & Pharmacology Authors: Vrachatis DA, Giannopoulos G, Kossyvakis C, Vasiliki P, Vavuranakis M, Papaioannou TG, Pagoni S, Pyrgakis VN, Cleman MW, Deftereos SG Tags: Curr Pharm Des Source Type: research

RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets.
CONCLUSION: Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia. PMID: 27510493 [PubMed - in process]
Source: Current Pharmaceutical Design - October 30, 2016 Category: Drugs & Pharmacology Authors: de Ramon L, Jarque M, Ripoll E, Bestard O, Grinyo JM, Torras J Tags: Curr Pharm Des Source Type: research

Statins in Stroke Prevention: Present and Future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipidmodifying therapies on stroke prevention. PMID: 27160755 [PubMed - in process]
Source: Current Pharmaceutical Design - October 30, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research